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Abstract The penta-EF hand (PEF) family of calcium binding
proteins includes grancalcin, pe£in, sorcin, calpain large and
small subunits as well as ALG-2. Systematic testing of the het-
erodimerization abilities of the PEF proteins using the yeast
two-hybrid and glutathione S-transferase pull-down assays re-
vealed the new ¢nding that grancalcin interacts strongly with
sorcin. In addition, sorcin and grancalcin can be co-immunopre-
cipitated from lysates of human umbilical vein endothelial cells.
Our results indicate that heterodimerization, in addition to dif-
ferential interactions with target proteins, might be a way to
regulate and ¢ne tune processes mediated by calcium binding
proteins of the penta-EF hand type.
) 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
Key words: EF hand calcium binding protein;
Protein^protein interaction; Penta-EF hand family protein;
Sorcin; Grancalcin; Apoptosis
1. Introduction
Calcium ions control a variety of cellular phenomena such
as muscle contraction, proliferation, di¡erentiation and apo-
ptosis. The speci¢city of calcium signaling is obtained by the
quality of the calcium signals, which has a temporal and spa-
tial aspect and is dependent on the amplitude of the calcium
transient [1]. In addition, the nature of the intracellular cal-
cium receptor mediating signal transduction is crucial [2]. One
structurally de¢ned subgroup of calcium binding proteins is
the PEF (penta-EF hand) family. This protein family com-
prises calpain large and small subunits, ALG-2 (apoptosis-
linked gene 2), pe£in, sorcin and grancalcin [3]. Based on se-
quence similarities, further subgroups can be made with pairs
of the small/large calpain subunits, ALG-2/pe£in and sorcin/
grancalcin.
The best characterized PEF family proteins are the large
and small subunits of calpain, which are known to heterodi-
merize to form an active protease [4,5]. A multitude of calpain
enzymes with di¡erent properties and/or di¡erent expression
patterns can be formed by heterodimerization of the small
subunit with the many di¡erent large subunits which carry
the sequence responsible for the catalytic activity [6].
Pe£in and ALG-2 have been shown to interact, but the
functional signi¢cance of this complex is so far unknown
[4]. Interestingly, in contrast to all PEF family protein homo-
dimers and the above mentioned calpain heterodimers, the
ALG-2/pe£in interaction only takes place in the absence of
calcium. We have previously shown that two isoforms of
ALG-2 exist [7]. The short form (ALG-2,1) lacks the two
residues Gly121 and Phe122, present in the long form (ALG-
2). In yeast two-hybrid experiments both ALG-2 isoforms
homo- and heterodimerize, but only the long isoform of
ALG-2 is able to interact with the target protein AIP1 [7].
Structural analysis of calpain [8], grancalcin [9], sorcin [10]
and ALG-2 [11] has shown that the PEF family proteins di-
merize by homotropic interaction in the ¢fth EF hand do-
main, which presumably does not bind calcium under physio-
logical conditions.
Here we present a systematic analysis of heterodimerization
of the PEF proteins using the yeast two-hybrid system. We
found that sorcin, a modulator of the ryanodine receptor and
expressed in many cell types [12], interacts in vitro and in vivo
with grancalcin, a protein with so far unde¢ned function,
which is expressed in a restricted range of cell types, mostly
of hematopoietic origin [13].
2. Materials and methods
2.1. Construction of GAL4 domain plasmids
pBDsorcin and pADsorcin: Sorcin cDNA was kindly provided by
C.E. Creutz [14]. The cDNA was ampli¢ed by polymerase chain re-
action (PCR) and cloned into the pBDGAL4 or pADGAL4 vector
(Stratagene).
pBDgrancalcin and pADgrancalcin : Human grancalcin cDNA
cloned into the pGEX2T vector was described in [15]. The cDNA
was ampli¢ed by PCR and cloned into the pBDGAL4 or pADGAL4
vector.
pADdeltape£in and pBDpe£in : The pcDNA3 vectors containing an
insert of the DNA sequence encoding the C-terminal 82 amino acids
of murine pe£in and full length pe£in were kindly provided by P. Vito
and subcloned into pADGAL4 or pBDGAL4.
2.2. Yeast strains and media
Two Saccharomyces cerevisiae strains were used in the two-hybrid
assays: YRG-2 (Stratagene; described in [7]) and SFY-526 (MatK,
ura3-52, his3-200, ade2-101, lys2-801, trp1-901, leu2-3, 112, canr,
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gal4-542, gal80-538, URA3: :UASGAL1-TATAGAL1-lacZ). Yeast cul-
tures were grown at 30‡C in either YPD medium (2% peptone, 1%
yeast extract, 2% glucose) or SD minimal medium (0.67% nitrogen
base, 18.2% D-sorbitol, 2% glucose) supplemented with amino acids.
2.3. Yeast transformation and phenotype analysis
The transformation of yeast with plasmid DNA was done accord-
ing to the lithium acetate TRAFO protocol [16]. The protein^protein
interaction phenotype was analyzed by the ability of transformed
yeast to grow on a medium lacking histidine and by the ability to
activate expression of the L-galactosidase gene as described previously
[7].
2.4. Immunodetection of the PEF proteins
Polyclonal antibodies against mouse ALG-2 were generated in rab-
bits and are described elsewhere [26]. Anti-grancalcin-1 rabbit antise-
rum was as described [15], anti-grancalcin-2 rabbit polyclonal was a
generous gift from A.W. Segal, and anti-sorcin monoclonal antibody
was from Zymed (San Francisco, CA, USA). All secondary horse-
radish peroxidase-conjugated antibodies were from Dako (DakoCy-
tomation, Glostrup, Denmark).
Proteins were separated by 12% sodium dodecyl sulfate^polyacryl-
amide gel electrophoresis (SDS^PAGE) at reducing conditions and
transferred onto a polyvinylidene di£uoride membrane (Hybond-P,
Amersham Biosciences, Sweden) according to standard procedures
[17]. Membranes were blocked in TBS-T (20 mM Tris^HCl, pH 7.4,
150 mM NaCl), 5% non-fat milk and 0.05% Tween 20 and stained
with antibody in the same bu¡er. Detection was performed using a
chemiluminescent ECL substrate (Amersham Biosciences, Sweden) ac-
cording to the manufacturer’s manual.
2.5. Expression of GST fusion proteins and pull-down assay
Human sorcin cDNA cloned into the pGEX-KG bacterial expres-
sion vector was kindly provided by C.E. Creutz [14]. The BL21-Co-
donPlus(DE3)-RP Escherichia coli strain was transformed with either
the pGEX-TK (ATCC) plasmid for glutathione S-transferase (GST)
expression or with pGEX-KG/GST-sorcin for expression of the GST^
sorcin fusion protein. Expression of the recombinant proteins was
induced at OD600 1.0 by 1 mM isopropyl-1-thio-L-D-galactopyrano-
side. Bacteria were harvested after 2.5 h by centrifugation at 2500Ug
at 4‡C for 15 min, and resuspended in 10 ml phosphate-bu¡ered saline
(140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4,
pH 7.3). Lysis was performed at room temperature for 25 min by
adding 1 mg/ml lysozyme, followed by freezing/thawing and adding
Triton X-100 to 1%. The bacterial debris was pelleted by centrifuga-
tion at 50 000Ug for 30 min at 4‡C and the supernatant was further
processed to puri¢cation on a 1 ml GSTRAP a⁄nity column (Amer-
sham Biosciences, Sweden) according to the manufacturer’s protocol.
The puri¢ed GST and GST^sorcin proteins were dialyzed against
KTT bu¡er (140 mM KCl, 20 mM Tris^HCl, pH 7.4, 0.1% Triton
X-100).
GST^sorcin or GST (5 Wg) was incubated with 2.5 mg of gluta-
thione-Sepharose 4B (Amersham Biosciences, Sweden) in the KKT
bu¡er at 4‡C overnight. The beads were spun down at 800Ug for
1 min and washed once with KTT bu¡er. 15 Wg of recombinant
human grancalcin [18] or 15 Wg ALG-2 [7] was added to the resin
and the binding was performed in KTT bu¡er with either 1 mM
CaCl2 or 1 mM EDTA, overnight at 4‡C. The beads were then
washed ¢ve times with 1 ml NTT bu¡er (150 mM NaCl, 20 mM
Tris^HCl, pH 7.4, 0.1% Triton X-100), resuspended in 50 Wl of
KTT and 50 Wl of 2USDS^PAGE sample bu¡er (100 mM Tris^
HCl, pH 6.8, 0.1% bromophenol blue, 4% SDS, 20% glycerol, 10%
L-mercaptoethanol) and boiled for 10 min. The samples were sub-
jected to SDS^PAGE followed by Western blot analysis.
2.6. Immunoprecipitation of the sorcin^grancalcin complex from
human cells
Human high umbilical vein endothelial cells (HUVEC) were grown
in 175 cm2 cell culture £asks to sub-con£uent density in EGM-2
Bullet kit medium (Clonetics, Belgium). The cells were lysed in a
bu¡er containing 150 mM NaCl, 1 mM MgCl2, 0.2% NP40, 25 mM
Tris^HCl, pH 7.5 and proteinase inhibitor mix (Sigma, St. Louis,
MO, USA). The extracts were pre-cleared by incubation with protein
A-Sepharose beads (Amersham Biosciences, Sweden) for 1 h at 4‡C
The beads were incubated with either anti-grancalcin or anti-sorcin
antiserum for 90 min at 4‡C and then washed four times with the lysis
bu¡er. Precipitation of immune complexes was performed overnight
at 4‡C.
3. Results
Since heterodimerization among some of the PEF proteins
had previously been reported, we tested whether the ALG-2
isoforms have dimerization partners within the PEF family.
The cDNA encoding ALG-2, ALG-2,1, pe£in, the 82 amino
acid long C-terminal part of pe£in (deltape£in), grancalcin,
sorcin, calpain small and large subunits were inserted into
the pBDGAL4 and pADGAL4 vectors and expressed pair-
wise in the YRG-2 yeast strain. The interaction phenotype
of the transformed yeast was analyzed by ¢lter lift assay.
We found that ALG-2 can bind the C-terminus of pe£in
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Fig. 1. Two-hybrid analysis of dimerization of the PEF proteins
shows that grancalcin interacts with sorcin. A: Filter lift assay. Het-
erodimerization abilities of grancalcin, pe£in and sorcin were tested.
BDT and ADT indicate the fusion partners of the proteins. B: Lu-
minescent L-galactosidase assay was applied to characterize the
grancalcin/sorcin interaction. The enzyme activity was measured in
lysates of four independent clones from each transformation. Values
(meanUS.D.) are given in arbitrary units.
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(data not shown). This result was expected since ALG-2 in-
teraction with this C-terminal fragment of pe£in was initially
observed by P. Vito, who provided this construct (unpub-
lished data, with permission of the author). While we were
performing these experiments, Maki et al. reported that pe£in
and ALG-2 indeed interact with each other, as shown by co-
immunoprecipitation from di¡erent cell lines [4]. Surprisingly,
no interaction between calpain large and small subunits was
observed in either YRG-2 or SFY-526 yeast strains in con-
trast to the results published by Sorimachi et al. [6].
By systematically testing PEF proteins for the ability to
heterodimerize (Fig. 1A) we found a so far undescribed inter-
action between sorcin and grancalcin (Fig. 1A,1). We also
showed that sorcin homodimerizes in yeast (Fig. 1A,6), where-
as grancalcin homodimerization cannot be tested since
BDgrancalcin activates the lacZ reporter gene alone (data
not shown).
The interaction of grancalcin with sorcin was quantitated
by a liquid luminescent L-galactosidase reporter gene assay
(Fig. 1B), which showed that heterodimerization is approxi-
mately 17 times stronger than sorcin homodimerization. To
con¢rm these results, a pull-down assay was performed using
recombinant GST^sorcin fusion protein and recombinant
grancalcin. Fig. 2A shows that the recombinant proteins are
able to heterodimerize in vitro in a calcium-independent man-
ner. As a control for the speci¢city of the GST^sorcin^gran-
calcin interaction, the ability of ALG-2 to bind to GST^sorcin
was also tested (Fig. 2B). Our results suggest that the sorcin/
grancalcin interaction is speci¢c.
The interaction between grancalcin and sorcin was further
con¢rmed by immunoprecipitation from HUVEC, where both
proteins were found to be expressed (Fig. 3). Thus, the two
PEF proteins, grancalcin and sorcin, interact in vivo.
4. Discussion
By a systematic analysis of PEF protein heterodimerization
we show here for the ¢rst time that sorcin and grancalcin
physically associate in vitro in a calcium-independent manner
in contrast to calpains or ALG-2/pe£in heterodimers, whose
association is in£uenced by calcium [4]. Moreover, sorcin and
grancalcin are expressed in HUVEC, from which they can be
co-immunoprecipitated. The ¢nding of the grancalcin^sorcin
interaction allows us to conclude that all so far known PEF
proteins have the potential to heterodimerize with one other
member of the PEF family.
Biological e¡ects of the grancalcin^sorcin interaction re-
main to be investigated. The fact that these proteins are co-
expressed at least in endothelial cells and cells of myeloid
origin [15] indicates that the grancalcin^sorcin interaction
may have a functional meaning.
It is well established that sorcin binds the ryanodine recep-
tor at micromolar calcium concentrations. In the cardiac
muscle this interaction leads to the inhibition of ryanodine
binding [19]. In contrast, interaction of sorcin with the ryano-
dine receptor from skeletal muscle potentiates the binding of
ryanodine [12]. Another interaction partner of sorcin is the
L-type calcium channel [20]. Taken together, these data indi-
cate that sorcin might be a modulator of the physical and
functional link between calcium release channels of the plas-
ma membrane and the sarcoplasmic reticulum. Grancalcin
might in£uence modulation of the sorcin target proteins via
high a⁄nity heterodimerization with sorcin.
Only one grancalcin interacting partner, L-plastin [18], a
leukocyte-speci¢c protein with a calcium-dependent actin bun-
dling activity [21], is known so far. L-plastin has been shown
to be involved in integrin activation and subsequent increased
adhesion of neutrophils after stimulation with in£ammatory
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Fig. 2. Grancalcin and sorcin interact in vitro. Pull-down assay.
GST^sorcin (lanes 2^7) or GST (lanes 8,9) were bound to gluta-
thione-Sepharose and incubated with either grancalcin (lanes 2,3,8,9)
or ALG-2 (lanes 4,5,10,11) in the presence of either 1 mM CaCl2
(lanes 2,4,6,8,10) or 1 mM EGTA (lanes 3,5,7,9,11). 10 ng grancal-
cin (lane 1) and 1.5 ng ALG-2 (lane 12) were run as controls for
immunodetection. A: Immunodetection with anti-grancalcin-1 anti-
body. Note: anti-grancalcin-1 antibody cross-reacts with sorcin.
B: Immunodetection with anti-ALG-2 antibody.
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Fig. 3. Interaction of grancalcin and sorcin in HUVEC. Co-immu-
noprecipitation of grancalcin and sorcin. Pre-immune rabbit serum
was used as a negative control (lane 1), immunoprecipitation with a
speci¢c anti-grancalcin-2 (lane 2) antibody, which in contrast to
anti-grancalcin-1 showed no cross-reactivity with sorcin, HUVEC
total lysate (lane 3). The immunostaining was performed with anti-
sorcin antibody.
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stimuli [22]. Interestingly, the grancalcin/L-plastin interaction
is inhibited by calcium, reminiscent of the interaction between
ALG-2 and pe£in [4]. How sorcin/grancalcin heterodimeriza-
tion could a¡ect the biological function of L-plastin cannot be
estimated since the functional consequences of grancalcin/L-
plastin interaction have not been investigated so far. As it has
been shown recently that grancalcin-de¢cient mice do not
have major defects in vital leukocyte e¡ector functions [23],
it can be speculated that sorcin could possibly ful¢ll the func-
tion(s) of grancalcin.
It has to be emphasized here that the PEF proteins can
share some of the targets. Both ALG-2 and sorcin interact
with annexin VII [14], a protein which was suggested to
play a role in apoptosis [24] and in the exocytotic membrane
fusion process in chroma⁄n cells [25]. In many cell types
sorcin and ALG-2 are co-expressed. However, ALG-2 does
not form a stable complex with sorcin meaning that the two
PEF proteins may independently modulate the activity of
their shared target. In the presence of the heterodimerization
partners (grancalcin for sorcin and pe£in or ALG-2,1 for
ALG-2) selection of the protein^protein interactions may oc-
cur. Thus, heterodimerization might be a way to regulate the
recruitment of di¡erent PEF proteins in response to e.g. cal-
cium transients in cells, which may allow a broad spectrum of
biological responses such as apoptosis, cell motility or exocy-
tosis to occur.
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